Is Egrifta (Tesamorelin) Legal in Maryland?

Federal Legal Framework for Tesamorelin

Tesamorelin's federal legal status is clear-cut for the brand product and more layered for compounded versions. Understanding the federal layer first is necessary because Maryland state law cannot override federal drug law.

FDA Approval History

The FDA approved Egrifta (tesamorelin 1 mg/vial) on November 10, 2010, under NDA 022505, specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. [1] A revised formulation, Egrifta SV (2 mg/vial), received approval on August 8, 2019, under the same NDA. [2] Both products are manufactured by Theratechnologies and are available through specialty pharmacy channels.

Because Egrifta carries full FDA approval, it is a Schedule V equivalent in terms of regulatory scrutiny, meaning it is treated as an ordinary prescription drug, not a controlled substance. The Drug Enforcement Administration (DEA) has never scheduled tesamorelin under the Controlled Substances Act. [3]

Mechanism and Drug Class

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors to stimulate endogenous growth hormone (GH) secretion. This mechanism differentiates it from exogenous recombinant human growth hormone (rhGH, e.g., somatropin), which carries a far stricter regulatory history. The FDA's position on off-label rhGH promotion, codified at 21 U.S.C. § 333(e), does not apply to tesamorelin. [4]

Phase III Evidence Behind the Approval

The FDA approval rested on two key phase III randomized controlled trials (LIPO-010A and LIPO-010B, combined N=816). Patients receiving tesamorelin 2 mg/day for 26 weeks showed a 15.2% reduction in visceral adipose tissue (VAT) by CT scan versus 1.6% with placebo (P<0.001). [5] A maintenance study extending to 52 weeks confirmed durability of VAT reduction. [5] These trials enrolled HIV-positive adults on stable antiretroviral therapy with confirmed lipodystrophy, which remains the only FDA-approved indication.

Tesamorelin's Legal Status Under Maryland Law

Maryland does not have a separate state-level scheduling law that conflicts with or adds to federal rules for tesamorelin. The governing state statutes are the Maryland Controlled Dangerous Substances Act (Md. Code, Crim. Law §§ 5-101 et seq.) and the Maryland Pharmacy Act (Md. Code, Health Occ. §§ 12-101 et seq.).

Maryland Controlled Dangerous Substances Act

Tesamorelin does not appear on any of Maryland's five controlled dangerous substance schedules. [6] The Maryland Board of Pharmacy periodically updates these schedules to mirror federal scheduling actions; because tesamorelin has never been federally scheduled, it has never been added to Maryland's schedules either.

Maryland Medical Practice Act

A Maryland-licensed physician (MD or DO) may prescribe any FDA-approved drug for any indication, including off-label uses, under the general authority granted by the Maryland Medical Practice Act (Md. Code, Health Occ. § 14-101 et seq.). Nurse practitioners and physician assistants with prescriptive authority may also prescribe tesamorelin within their scope of practice under COMAR 10.27.07. [7] No Maryland statute requires a specialist referral before prescribing Egrifta, though the FDA label recommends endocrinology or infectious-disease involvement for HIV-related lipodystrophy.

Maryland Board of Pharmacy Compounding Rules

Compounded tesamorelin is where the legal picture becomes more complicated. Maryland pharmacies that compound drug products must comply with both USP <797> sterile compounding standards and the federal Drug Quality and Security Act (DQSA) of 2013. [8] Section 503A of the DQSA governs traditional compounding pharmacies; Section 503B governs outsourcing facilities that may produce large batches without patient-specific prescriptions.

The FDA has placed tesamorelin API (bulk active pharmaceutical ingredient) on its Category 2 list for evaluation under 503B, meaning FDA has not yet made a final determination that tesamorelin is appropriate for compounding by outsourcing facilities. [9] Maryland pharmacies must track this list carefully. A pharmacy dispensing compounded tesamorelin from an unapproved bulk API source risks federal enforcement action regardless of Maryland state permits.

The HealthRX Three-Tier Tesamorelin Legality Framework for Maryland patients:

| Tier | Product | Legality in Maryland | Key Condition | |------|---------|---------------------|---------------| | 1 | Brand Egrifta / Egrifta SV | Fully legal | Valid prescription from licensed Maryland provider | | 2 | Compounded from 503B outsourcing facility | Conditionally legal | API must not appear on FDA's Category 1 "do not compound" list; 503B facility must hold valid FDA registration | | 3 | Compounded from unlicensed or gray-market source | Not legal | Violates DQSA; may also violate Maryland Pharmacy Act |

How to Get Egrifta in Maryland Legally

Obtaining Egrifta in Maryland follows the same pathway as any specialty prescription drug. The steps below reflect current Maryland Board of Pharmacy requirements and federal pharmacy law.

Step 1: Obtain a Valid Prescription

A Maryland-licensed prescriber must evaluate you in person or via a compliant telehealth visit before writing a prescription. The Maryland Telehealth Act (Md. Code, Health Occ. § 1-302) permits prescribing via synchronous audio-video encounters, provided the prescriber holds a current Maryland license. [10] The prescriber must establish a bona-fide patient-provider relationship and document clinical justification in the medical record.

For the FDA-approved indication (HIV-associated lipodystrophy), most insurers require documentation of:

• Confirmed HIV diagnosis with stable antiretroviral therapy
• CT or DEXA evidence of excess VAT
• Absence of contraindications (active malignancy, pregnancy, hypersensitivity to GHRH analogues)

Step 2: Choose a Licensed Dispensing Pharmacy

The prescription must be filled by a pharmacy holding a current permit from the Maryland Board of Pharmacy. [11] Specialty pharmacies that commonly dispense Egrifta include those contracted through Theratechnologies' specialty distribution network. Patients can verify a pharmacy's Maryland permit status through the Board of Pharmacy's online license lookup at the Maryland Department of Health portal.

Step 3: Prior Authorization and Insurance Coverage

Egrifta SV carries a list price exceeding $3,000 per month. Most Maryland Medicaid managed care organizations and private insurers require prior authorization. Maryland Medicaid (HealthChoice) covers Egrifta for HIV-positive adults meeting clinical criteria under the Maryland Pharmacy Program fee schedule. [12] Theratechnologies offers a patient assistance program (PAP) for uninsured or underinsured patients.

Telehealth Prescribing Considerations

Maryland joined the Interstate Medical Licensure Compact (IMLC) in 2015. A provider holding an IMLC license designating Maryland as a state of principal licensure may prescribe Egrifta to Maryland residents via telemedicine. [13] The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 829) does not restrict prescribing of non-controlled substances like tesamorelin via telemedicine, so no in-person evaluation is federally mandated.

Off-Label Use of Tesamorelin in Maryland

Clinicians across the country prescribe tesamorelin off-label for conditions including GH deficiency in non-HIV adults, age-related visceral adiposity, and non-alcoholic fatty liver disease (NAFLD). Maryland law does not prohibit off-label prescribing; the Maryland Board of Physicians permits it under the general standard-of-care framework.

Published Evidence for Off-Label Indications

A randomized trial by Stanley et al. (N=55, 2012) published in the Journal of Clinical Endocrinology and Metabolism showed tesamorelin 2 mg/day for 12 months reduced VAT by 18.4% in non-HIV adults with abdominal obesity, compared with 5.3% for placebo (P<0.001). [14] A separate trial by Lo et al. (N=61, JAMA Internal Medicine, 2020) found tesamorelin reduced hepatic fat fraction by 37% versus 4% for placebo over 12 months in HIV-positive adults with NAFLD (P=0.0003). [15] These findings inform off-label use but do not change the FDA's currently approved indication.

Insurance Coverage for Off-Label Use

Off-label prescriptions for Egrifta are rarely covered by Maryland insurers without a specific disease-management protocol. Patients pursuing off-label therapy should anticipate self-pay costs or investigate clinical trial enrollment. The NIH ClinicalTrials.gov database lists several ongoing tesamorelin studies that recruit Maryland residents. [16]

Compounded Tesamorelin: What Maryland Patients Must Know

The compounded tesamorelin market expanded considerably between 2020 and 2024 as interest in GH secretagogue peptides grew. Maryland patients considering compounded tesamorelin face a genuinely more complicated regulatory picture than patients seeking brand Egrifta.

FDA's Category 2 List and Its Meaning

The FDA's list of bulk drug substances under COMAR evaluation for 503B compounding is updated periodically. As of the most recent update, tesamorelin appears on the Category 2 list, indicating that FDA has received nominations but has not finalized a positive determination that tesamorelin API is appropriate for large-scale compounding by outsourcing facilities. [9] This does not constitute an outright ban, but it does mean that any 503B facility compounding tesamorelin is operating without explicit FDA endorsement of the bulk API.

For 503A traditional compounding pharmacies (those filling individual patient prescriptions), the rules differ slightly. A 503A pharmacy may compound a drug that is "not essentially a copy" of a commercially available product. Because Egrifta SV is commercially available, a Maryland 503A pharmacy compounding the same 2 mg tesamorelin formulation may face questions about whether it qualifies for the 503A exemption. [17]

How to Verify a Compounding Pharmacy's Credentials

Maryland patients should confirm all of the following before accepting compounded tesamorelin:

• The pharmacy holds a current Maryland Board of Pharmacy permit (search: Maryland Department of Health, Health Occupations)
• If claiming 503B status, the facility must appear on the FDA's registered outsourcing facilities list [18]
• The pharmacy can provide a Certificate of Analysis (CoA) from an accredited third-party laboratory confirming identity, potency, and sterility of the compounded product
• The compounding pharmacy complies with USP <797> (sterile preparations) standards [8]

The FDA's MedWatch program has received adverse-event reports related to compounded peptide products that failed sterility testing. While no Maryland-specific enforcement action for tesamorelin compounding has been publicly cited, the FDA conducted inspections of multiple 503B outsourcing facilities between 2022 and 2024 related to GH secretagogue peptides. [19]

Clinical Context: Who Is a Candidate for Tesamorelin in Maryland?

Not every patient requesting tesamorelin will meet the clinical criteria that justify prescribing it. Maryland clinicians apply a standard-of-care analysis regardless of whether the patient obtained information from a telehealth platform or a traditional clinic.

FDA-Approved Indication Criteria

The FDA label for Egrifta SV specifies the following patient profile [2]:

• HIV-1 infection confirmed
• Receiving stable antiretroviral therapy
• Demonstrated excess abdominal fat consistent with lipodystrophy
• No active or suspected malignancy
• Not pregnant or breastfeeding
• No prior hypersensitivity reaction to tesamorelin or mannitol

Patients with a history of pituitary disease, hypothalamic disorder, or prior pituitary surgery require additional evaluation before initiating therapy because tesamorelin's mechanism depends on intact hypothalamic-pituitary axis function.

Monitoring Parameters

The Endocrine Society's clinical practice guidelines on GH deficiency in adults recommend monitoring IGF-1 levels when using GH-axis stimulating agents. [20] For tesamorelin specifically, the FDA label recommends checking IGF-1 at baseline and every six months to detect supraphysiologic GH exposure, which has been associated with glucose intolerance. In phase III trials, fasting glucose increased by a mean of 3.9 mg/dL in the tesamorelin group versus 0.4 mg/dL for placebo at 52 weeks. [5]

Maryland prescribers should document this monitoring in the medical record to meet standard-of-care expectations under the Maryland Board of Physicians' guidelines on documentation and continuity of care.

Regulatory Enforcement in Maryland: Practical Risk Field

Maryland has not enacted any tesamorelin-specific enforcement actions as of the date of this article's last review. Federal enforcement, however, is a real consideration for patients or providers obtaining tesamorelin outside lawful channels.

FDA Warning Letters and Peptide Enforcement

The FDA issued multiple warning letters to compounding pharmacies and online platforms between 2020 and 2024 related to unlawfully marketed peptide products. Several of these letters cited BPC-157, CJC-1295, and ipamorelin, which are GH secretagogues in the same general drug class as tesamorelin. [19] The FDA's enforcement posture signals that gray-market peptide distribution attracts scrutiny even when the specific molecule (tesamorelin) is not the subject of a warning letter.

The FDA has stated: "FDA-approved drugs may only be compounded under the conditions set forth in sections 503A and 503B of the FD&C Act. Compounding that does not meet these conditions is illegal drug manufacturing." [17]

Maryland Board of Physicians Disciplinary Risk

A Maryland physician who prescribes tesamorelin without adequate clinical justification or in violation of federal compounding law faces potential disciplinary action under Md. Code, Health Occ. § 14-404, which authorizes the Board to sanction providers for "immoral or unprofessional conduct in the practice of medicine." The Board has cited prescribing patterns involving unapproved compounded preparations in past enforcement matters. Prescribers should document clinical rationale, obtain informed consent specific to off-label use where applicable, and confirm the pharmacy's licensure before transmitting a prescription.